Φορτώνει......
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Background: The aim was to assess the safety and tolerability of the insulin aspart biosimilar/follow-on product SAR341402 (100 U/mL solution; SAR-Asp) and originator insulin aspart (100 U/mL; NN-Asp; NovoLog(®)) self-administered through an insulin pump. Materials and Methods: This randomized, open...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Diabetes Technol Ther |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Mary Ann Liebert, Inc., publishers
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7478191/ https://ncbi.nlm.nih.gov/pubmed/31833801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2019.0446 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|